Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	22.69B +31.5%
Revenue (ttm)	2.40B -10.6%
Net Income	285.77M +118.7%
EPS	0.18 +115.5%
Shares Out	1.60B
PE Ratio	79.97
Forward PE	75.68
Dividend	0.04 (0.29%)
Ex-Dividend Date	Jan 9, 2026

Volume	69,024,878
Average Volume	88,297,311
Open	14.43
Previous Close	14.19
Day's Range	13.99 - 14.65
52-Week Range	10.01 - 16.23
Beta	0.42
RSI	57.64
Earnings Date	Apr 28, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the b...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,981
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2025, Walvax Biotechnology's revenue was 2.42 billion, a decrease of -14.29% compared to the previous year's 2.82 billion. Earnings were 177.74 million, an increase of 25.03%.